Kyle's Board

[kyle_anderson]

MRIC getting promoted by "Stock Haven" starting January 22, 2013 @ 8:47 AM

Some quick due diligence for MRI Interventions Inc

O/S: 48,018,000 shares as of November 8, 2012
A/S: 100,000,000 shares as of March 31, 2012

Market tier: OTCQB
Market Capitalization: $84,031,500

The promoter for this "investor awareness" campaign is "Stock Haven".
These are the last few stocks (ordered by promotion start date) that "Stock Haven" has campaigned for and the closing share price for that day and stock

1. IMSC - Implant Sciences Corp.
The opening price on Jan. 16, 2013 for IMSC was 1.20, and the end of day closing price was 1.37 on the first day of that promotion. This was a gain of 14%

2. NWTR - New Western Energy Corp
The opening price on Dec. 31, 2012 for NWTR was 0.810, and the end of day closing price was 0.940 on the first day of that promotion. This was a gain of 16%

3. FEEC - Far East Energy Corp.
The opening price on Nov. 27, 2012 for FEEC was 0.096, and the end of day closing price was 0.110 on the first day of that promotion. This was a gain of 15%

4. MRIC - MRI Interventions Inc
The opening price on Nov. 12, 2012 for MRIC was 1.63, and the end of day closing price was 1.90 on the first day of that promotion. This was a gain of 16%

5. TAGG - TagLikeMe Corp.
The opening price on Oct. 2, 2012 for TAGG was 0.115, and the end of day closing price was 0.079 on the first day of that promotion. This was a loss of -31%


This is one of the newsletters I got (at 8:47 AM CST) in my inbox:

Dear subscriber,

We'd like to introduce to you a mid-term investment opportunity with a potential return on investment of 200% or even more AntriaBio, Inc. FMYYD

A Bit of History

We profiled MRI Interventional MRIC in June last year. Our subscribers were first on a market to join MRIC stock at the rock-bottom prices. MRIC shares rose from $1.10 to over $4 per share in just a bit over of the four trading weeks. We expect that AntriaBio stock will even outperform MRIC's run-up at the similar time-frame.

In January 7th, 2013, AntriaBio of $100M in prior technology, formulation, manufacturing and intellectual property assets from PR Pharmaceuticals. Following this announcement, Fits My Style, Inc. a.k.a. merger shell completed the name change to AntriaBio and 1 to 6 forward split of its shares. On January 11th, 2013, AntriaBio FMYYD stock has begun trading on the OTC Bulleting Board.

Market Technology

AntriaBio's lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin. AB101 targets patients with type 1 and type 2 diabetes that require basal insulin for the control of hyperglycemia. Product allows to release insulin slowly over a period of one week without an adverse initial burst of insulin, thus offering a HUGE technology advantage to once-a-day insulin injections from the leading manufacturers such as Novo Nordisk NYSE NVO Sanofi-Aventis NYSE SNY. Furthermore, AntriaBio's technology is compatible with other diabetes medications by sustained insulin level or may even complement effects from those medications.

From AntriaBio's presentation at Biotech Showcase 2013 Conference in San Francisco

AB101 Opportunity

If approved, the Company believes that AB101 will result in greater patient convenience and compliance once weekly delivery versus once daily delivery
Lantus, the bestselling basal insulin therapy offered by Sanofi-Aventis has sales annual in excess of $5B
Novo Nordisks basal insulin, Levemir, has $2B in annual sales
In North America, basal insulin commands a 47% share of total insulin usage. There is a significant opportunity for AB101 to enter new markets where basal insulin has limited penetration, including Europe 36%, Japan and Korea 29%, and China 13%.

At glance

The insulin segment of the U.S. diabetes drug market exceeded $12B in 2011. AntriaBio's AB101 if approved has the potential to be a noteworthy player on this market with a product that represents a considerable advance in basal insulin delivery.

Simple math for the AB101 potentials when approved with $200MM in annual sales very conservative estimate in comparison to $5B Lantus sales revenues FMYYD shares should be valued from 4X to 10X of their current market price.

Last, but not least AntriaBio is a potential buy-out candidate even at its preclinical products development stages. The response on insulin injections for animals is identical to humans when those injections are administered in the right sequence. AB101 does not contain any new excipients, thus safety and efficacy data study could make the AB101 approval-ready buy-out ready in just 18-24 months.

Fasten your seatbelt drive FMYYD with us
Happy Trading
PennyStockHaven Staff

Disclaimer we are long on FMYYD

If you no longer wish to receive these emails, please reply to this message with Unsubscribe in the subject line or simply click on the following link

PennyStockHaven.com
10660 Yonge St
Richmond Hill, Ontario L1C 1C4
CA

the marketing policy.

A bit more information on this promotion is available here at this link:

https://www.otcdynamics.com/index.php/mric-mri-interventions-inc-getting-a-promotion-starting-january-22-2013/


I use custom software that tracks all major stock promotions and keeps records of their performances. I am NOT affiliated with any stock promoter and I provide this information as a courtesy to supplement your own due diligence.